文献速递临床试验与 GCP

双联抗血小板治疗与阿替普酶治疗轻型非致残性急性缺血性卒中患者的比较:ARAMIS随机临床试验

Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

ARAMIS多中心开放标签盲法终点非劣效随机试验纳入中国38家医院760例发病4.5小时内的轻型非致残性急性缺血性卒中患者(NIHSS≤5分),比较双联抗血小板治疗(DAPT)与静脉阿替普酶。90天时DAPT组93.8%与阿替普酶组91.4%达到优良功能结局(风险差2.3%,95%CI -1.5%至6.2%),单侧97.5%CI下限-1.5%大于非劣效界值-4.5%(非劣效P<.001),DAPT不劣于阿替普酶。

要点

  • 轻型非致残性急性缺血性卒中发病4.5小时内,DAPT在90天优良功能结局上不劣于静脉阿替普酶。
  • 90天优良功能结局:DAPT组93.8%(346/369) vs 阿替普酶组91.4%(320/350)。
  • 症状性颅内出血:DAPT组1/371(0.3%) vs 阿替普酶组3/351(0.9%)。

核心结论

  • 在发病4.5小时内的轻型非致残性急性缺血性卒中患者中,就90天优良功能结局而言,DAPT不劣于静脉阿替普酶。

研究设计与样本

  • 多中心、开放标签、盲法终点的非劣效随机临床试验,在中国38家医院开展,2018年10月至2022年4月入组,最终随访2022年7月18日。
  • 纳入760例急性轻型非致残性卒中患者(NIHSS评分≤5分,且若干关键单项评分≤1分;量表范围0-42分)。
  • 随机分为DAPT组(n=393)和阿替普酶组(n=367),主分析采用全分析集(所有随机化且至少完成1次疗效评估的参与者)。

主要发现

  • 90天优良功能结局(改良Rankin量表评分0或1分):DAPT组93.8%(346/369) vs 阿替普酶组91.4%(320/350),风险差2.3%(95%CI -1.5%至6.2%),粗相对危险度1.38(95%CI 0.81-2.32)。
  • 非劣效检验:未校正单侧97.5%CI下限为-1.5%,大于非劣效界值-4.5%(非劣效P<.001)。
  • 90天症状性颅内出血:DAPT组1/371(0.3%) vs 阿替普酶组3/351(0.9%)。
  • 760例随机患者中719例(94.6%)完成试验;中位(IQR)年龄64(57-71)岁,女性223例(31.0%),中位(IQR)NIHSS评分2(1-3)分。

关键数值与推荐

  • 非劣效界值定义为风险差的单侧97.5%CI下限大于或等于-4.5%。
  • DAPT方案:首日氯吡格雷300 mg,随后75 mg每日一次共12(±2)天;首日阿司匹林100 mg,随后100 mg每日一次共12(±2)天;之后按指南抗血小板治疗至90天。
  • 阿替普酶方案:静脉阿替普酶0.9 mg/kg(最大剂量90 mg),溶栓后24小时开始按指南抗血小板治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intravenous thrombolysis is increasingly used in patients with minor stroke, but its benefit in patients with minor nondisabling stroke is unknown. OBJECTIVE: To investigate whether dual antiplatelet therapy (DAPT) is noninferior to intravenous thrombolysis among patients with minor nondisabling acute ischemic stroke. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, blinded end point, noninferiority randomized clinical trial included 760 patients with acute minor nondisabling stroke (National Institutes of Health Stroke Scale [NIHSS] score ≤5, with ≤1 point on the NIHSS in several key single-item scores; scale range, 0-42). The trial was conducted at 38 hospitals in China from October 2018 through April 2022. The final follow-up was on July 18, 2022. INTERVENTIONS: Eligible patients were randomized within 4.5 hours of symptom onset to the DAPT group (n = 393), who received 300 mg of clopidogrel on the first day followed by 75 mg daily for 12 (±2) days, 100 mg of aspirin on the first day followed by 100 mg daily for 12 (±2) days, and guideline-based antiplatelet treatment until 90 days, or the alteplase group (n = 367), who received intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg) followed by guideline-based antiplatelet treatment beginning 24 hours after receipt of alteplase. MAIN OUTCOMES AND MEASURES: The primary end point was excellent functional outcome, defined as a modified Rankin Scale score of 0 or 1 (range, 0-6), at 90 days. The noninferiority of DAPT to alteplase was defined on the basis of a lower boundary of the 1-sided 97.5% CI of the risk difference greater than or equal to -4.5% (noninferiority margin) based on a full analysis set, which included all randomized participants with at least 1 efficacy evaluation, regardless of treatment group. The 90-day end points were assessed in a blinded manner. A safety end point was symptomatic intracerebral hemorrhage up to 90 days. RESULTS: Among 760 eligible randomized patients (median [IQR] age, 64 [57-71] years; 223 [31.0%] women; median [IQR] NIHSS score, 2 [1-3]), 719 (94.6%) completed the trial. At 90 days, 93.8% of patients (346/369) in the DAPT group and 91.4% (320/350) in the alteplase group had an excellent functional outcome (risk difference, 2.3% [95% CI, -1.5% to 6.2%]; crude relative risk, 1.38 [95% CI, 0.81-2.32]). The unadjusted lower limit of the 1-sided 97.5% CI was -1.5%, which is larger than the -4.5% noninferiority margin (P for noninferiority <.001). Symptomatic intracerebral hemorrhage at 90 days occurred in 1 of 371 participants (0.3%) in the DAPT group and 3 of 351 (0.9%) in the alteplase group. CONCLUSIONS AND RELEVANCE: Among patients with minor nondisabling acute ischemic stroke presenting within 4.5 hours of symptom onset, DAPT was noninferior to intravenous alteplase with regard to excellent functional outcome at 90 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03661411.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Chen HS, Cui Y, Zhou ZH, et al. Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial. JAMA. 2023. PMID: 37367978. doi:10.1001/jama.2023.7827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。